Table 1 Demographic and clinical data

Eye (OD : OS)

49 : 40

26 : 21

23 : 19

0.958

Age

62.5 ± 10.9

60.9 ± 11.7

64.2 ± 9.8

0.160

Sex (male : female)

56 : 33

30 : 17

26 : 16

0.851

Follow-up duration (months)

32.0 ± 21.8

30.0 ± 22.7

34.3 ± 20.8

0.348

Number of anti-VEGF injections in first year

4.1 ± 2.3

2.4 ± 1.2

5.9 ± 1.6

< 0.001

Baseline logMAR BCVA

0.88 ± 0.56

0.84 ± 0.60

0.93 ± 0.52

0.416

LogMAR BCVA at 1 year

0.60 ± 0.46

0.50 ± 0.49

0.72 ± 0.40

0.024

Pre-treatment CRT (μm)

495 ± 175

451 ± 157

544 ± 183

0.011

Post-treatment best CRT (μm)

253 ± 52

233 ± 33

275 ± 61

< 0.001

CRT at 1 year (μm)

329 ± 131

252 ± 38

414 ± 146

< 0.001

Type of BRVO (major : macular)

61 : 28

30 : 17

31 : 11

0.311

Type of macular edema on OCT

  Cystoid macular edema (yes : no)

47 : 42

21 : 26

26 : 16

0.104

  Diffuse retinal thickening (yes : no)

41 : 48

24 : 23

17 : 25

0.317

  Serous retinal detachment (yes : no)

13 : 76

6 : 41

7 : 35

0.603

Mean gray value over parafoveal region

25.0 ± 21.1

14.1 ± 12.5

37.3 ± 22.1

< 0.001

Mean gray value over perifoveal region

23.3 ± 15.1

14.9 ± 8.9

32.7 ± 15.0

< 0.001